Duns company on germ control

John Lamont MSP visiting the Aqualution Systems production unit in Duns
John Lamont MSP visiting the Aqualution Systems production unit in Duns

Duns based Aqualution Systems Ltd were visited by local MSP John Lamont for the launch of their new on-site, on-demand infection control product.

Aqualution’s managing director, Nick Meakin, said: “We welcome John Lamont at an incredibly exciting time for our business. Our mission is to improve the health and well-being of people everywhere. To achieve this goal, we must protect the environments in which we work, live, play and where we are cared for.

“The majority of existing disinfectants on the market are compromised in the way that they are used and can therefore be ineffective in eradicating viruses, harmful germs and pathogens. This is one reason why infection control in hospitals continues to be a major issue despite all of the resource put into resolving the problems. Furthermore many are toxic and energy and labour intensive. Due to the speed with which our active works, in addition to being safe, our products deliver results within the contact times that are available in a busy cleaning schedule”.

“Our main manufacturing site, and research and development team is based at our site in Duns. We also have manufacturing capabilities in 34 countries and growth plans that will see us deliver a turnover of £150 million within five years”.

“January 2014 will see the launch of a brand new state of the art, on-site, on-demand delivery system which can be easily installed into even the smallest of sites, and only requires a 13 amp plug and mains water supply.”

After touring the factory John Lamont MSP said: “Aqualution are a great example of how a business can thrive in the Borders.

“Since 2009 they have gone from strength to strength and now produce a series of world leading products that are sold around the world. It was great to be able to get the chance to meet the people working at the Duns site and to see the effort that goes into developing products such as Salvesan.”